Share this article
LAS VEGAS, Jan. 12, 2021 /PRNewswire/ DelveInsight s
Diffuse Large B-cell Lymphoma Market Research Report report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Diffuse Large B-cell Lymphoma Market Report s Few Key Highlights
CAR-T therapies and the pipeline agents,
Lisocabtagene maraleucel, are expected to contribute significantly to revenues because of the premium pricing and clinical benefits in Relapsed-Refractory (R/R) patients.
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020 Commercial Launch of XPOVIO in Expanded Multiple Myeloma Indication Fully Underway
News provided by
Share this article
Share this article
NEWTON, Mass., Jan. 11, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company s first-in-class, oral Selective Inhibitor of Nuclear Export
December 21, 2020 Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date -
SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for oral XPOVIO
(2)
DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple
Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO(R) Addressable Patient Population - Oral XPOVIO(R) is Now the Only Approved Multiple Myeloma Drug Indicated
TodayIR: Antengene Announces its U S Partner, -2- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.